Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
Eli Lilly (LLY) Has a Powerful Growth Flywheel Beyond Its GLP-1 Success
Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher inter…
Eli Lilly (LLY) Just Overtook the 50-Day Moving Average
Eli Lilly (LLY) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, LLY broke through the 50-day moving average, which suggests a short-term bullish trend. The 50-day simple m…
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
Eli Lilly and Company's LLY stock has declined around 2.3% in the past three months despite very strong underlying business momentum. The main issue is expectations and valuation rather than a deterioration in fundamentals. Investors have…
If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well. Another fact…
How to invest in healthcare stocks without picking the next Eli Lilly
It's always tempting as an investor to try to find the next big winner, and healthcare stocks have been one area where many investors are looking. The explosion in the popularity of GLP-1 medications such as Ozempic and Mounjaro is one suc…
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
Eli Lilly LLY is expected to deliver another quarter of robust growth from its oncology portfolio when it reports third-quarter results on Oct. 29. The franchise generated $4.84 billion in revenues in the first half of 2026, up 11% year ov…
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswire/ -- At Veeva R&D and Quality Summit o…
Dow Jones Futures Fall As Oil Prices, Treasury Yields Jump; Samsung, Micron, Taiwan Semi, Sandisk In Focus
Futures fell as oil prices and Treasury yields jumped. Samsung, Taiwan Semi results fall to cheer investors. Continue Reading
Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?
InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to pursue up to five drug targets addressing critical unmet medical needs. The partnership headlines arrive aft…
Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value
(Bloomberg) -- Isomorphic Labs, an AI-powered drug discovery startup spun out of Alphabet Inc.'s Google DeepMind, is in early talks to raise new funds at a valuation of at least $40 billion, according to people familiar with the effort. Mo…
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY). After contrasting their share-price performance, they asked which offered better upside over…
Dow Jones Futures: Yields Move Higher; Samsung, Micron, Taiwan Semi, Sandisk In Focus
The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news are relevant for Micron, Sandisk and more. Continue Reading
Dow Jones Futures Fall As Yields Move Higher; Samsung, Micron, Taiwan Semi, Sandisk In Focus
The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news are relevant for Micron, Sandisk and more. Continue Reading
Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?
Pfizer Inc. (NYSE:PFE) looks cheap based on its forward P/E, but its earnings outlook helps explain the discount. But unlike Johnson & Johnson or Eli Lilly, Pfizer's low earnings multiple is not being driven lower by rapid earnings growth.…
Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?
Johnson & Johnson (NYSE:JNJ) is starting to look less like a defensive healthcare giant and more like a growth story. The harder question is how much investors should pay before that growth fully arrives. The company raised its 2026 outloo…
Dow Jones Futures: Stocks Pare Losses As Yields Back Off; Samsung, Micron, Taiwan Semi, Sandisk In Focus
The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news will be key for Micron, Sandisk and more. Continue Reading
What Does Eli Lilly (LLY) Gain From This $870 Million Drug Discovery Deal?
Eli Lilly (NYSE:LLY) expanded its drug discovery alliance with Gate Bioscience in a potential US$870m multi-year deal. The broadened collaboration targets difficult-to-drug proteins using Gate Bioscience's discovery platform across high un…
Nasdaq and S&P Hold Weekly Gains as Small Caps and Dow Slip Midweek
PITTSBURGH, Oct. 7, 2026 /PRNewswire/ -- Stock Preachers Market Commentary - Major averages split this week as the Nasdaq Composite and S&P 500 held onto gains while the Dow Jones Industrial Average and Russell 2000 turned lower. The Nasda…
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management's Multi-Strategy Composite returned -1…
VKTX Advances Obesity Program With New Oral Maintenance Study
Viking Therapeutics VKTX announced the initiation of a clinical study evaluating oral maintenance dosing of its lead obesity candidate, VK2735. The study, which is designed to enroll approximately 195 adults with obesity, will evaluate whe…
Can Redwire's Microgravity Pharma Work Create New Revenue Streams?
Redwire Corporation RDW is expanding its microgravity capabilities beyond traditional space infrastructure into pharmaceutical research and development. The company's Pharmaceutical In-Space Laboratory – Bio-crystal Optimization Experiment…
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo NVO has an opportunity to extract greater value from semaglutide by expanding its use beyond traditional diabetes, obesity and cardiovascular indications. This strategy is increasingly relevant as the company faces intense competition…
Why the traditional 60/40 portfolio might be dead
Catalyst Funds Chief Investment Officer David Miller and Washington Crossing Advisors Senior Portfolio Manager Chad Morganlander chat about the reality of the 60/40 portfolio in today's volatile economy, and break down why traditional inve…
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Eli Lilly (LLY) was up +1.26% at $1,157.49. The stock's change was more than the S&P 500's daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increas…
Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO
[IPO Concept with Stock Market Graphs] AlexSecret Anti-inflammatory drug developer TRex Bio (TRXB [https://seekingalpha.com/symbol/TRXB]), whose backers include Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), disclosed additional de…
General Medicine Raises $120 Million to Build the Healthcare Store
Customers nationwide can search, compare, and buy care, seeing upfront what it costs with and without insurance. The company's product catalog now includes more than 2,900 products and services across medications, labs, telehealth, special…
Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis. There’s a Catch Investors Shouldn’t Miss
At the European Association for the Study of Diabetes meeting in Milan, Eli Lilly and Company (NYSE:LLY) presented data showing that its oral GLP-1 pill, Foundayo, delivered greater weight loss and better blood sugar control than oral sema…
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Shares of Viking Therapeutics VKTX have lost about 16% over the past month, despite the positive results from a maintenance dosing study evaluating its lead obesity candidate, VK2735. The recent weakness appears to be driven largely by inv…
2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Headwinds
2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Headwinds Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, l…
Stocks Are Ignoring the Bond Market Warning at Their Peril
Tech stocks drive markets to record highs, bond yield fears, Nvidia shares surge, and more things to know today. Continue Reading
insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab
SOUTH SAN FRANCISCO, Calif., October 06, 2026--(BUSINESS WIRE)--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insi…
Ginkgo Bioworks surges 21%; up 120% over last month
[Business graph, chart green background.Copy space] design master * Gingko Bioworks (DNA [https://seekingalpha.com/symbol/DNA]) closed Monday up ~21% as options trading surged. * The stock has been on a tear of late. Over the last month, s…
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Wall Street closed out the week split down the middle, with the Nasdaq Composite punching to a 27,190.86 close on a 1.19% daily jump while the Dow Jones Industrial Av…
Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It’s Moving Beyond GLP-1s.
The company’s experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration. Continue Reading